Adage Capital Partners’s Aclaris Therapeutics ACRS Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Shares Change %	Capital Flow	Portfolio Weight	Portfolio Position
2025 Q2	$13.7M	Hold	9,627,304	–	–	0.02%	543
2025 Q1	$14.7M	Hold	9,627,304	–	–	0.03%	491
2024 Q4	$23.9M	Buy	+9,627,304	New	+$23.9M	0.04%	397
2023 Q4	–	Sell	-1,000,000	Closed	-$6.85M	–	844
2023 Q3	$6.85M	Hold	1,000,000	–	–	0.02%	626
2023 Q2	$10.4M	Sell	1,000,000 -180,000	-15%	-$1.87M	0.02%	567
2023 Q1	$9.55M	Buy	1,180,000 +480,000	+69%	+$3.88M	0.02%	628
2022 Q4	$11M	Hold	700,000	–	–	0.03%	611
2022 Q3	$11M	Buy	700,000 +75,000	+12%	+$1.18M	0.03%	613
2022 Q2	$8.73M	Buy	625,000 +200,000	+47%	+$2.79M	0.02%	701
2022 Q1	$7.33M	Sell	425,000 -474,997	-53%	-$8.19M	0.01%	779
2021 Q4	$13.1M	Sell	899,997 -175,369	-16%	-$2.55M	0.02%	618
2021 Q3	$19.4M	Sell	1,075,366 -924,634	-46%	-$16.6M	0.04%	467
2021 Q2	$35.1M	Sell	2,000,000 -1,200,000	-38%	-$21.1M	0.07%	295
2021 Q1	$80.6M	Buy	3,200,000 +950,000	+42%	+$23.9M	0.16%	143
2020 Q4	$14.6M	Sell	2,250,000 -250,000	-10%	-$1.62M	0.03%	504
2020 Q3	$6.43M	Hold	2,500,000	–	–	0.02%	595
2020 Q2	$4.05M	Buy	2,500,000 +500,000	+25%	+$810K	0.01%	644
2020 Q1	$2.08M	Buy	2,000,000 +1,300,000	+186%	+$1.35M	0.01%	654
2019 Q4	$1.32M	Hold	700,000	–	–	﹤0.01%	671
2019 Q3	$756K	Hold	700,000	–	–	﹤0.01%	693
2019 Q2	$1.53M	Buy	+700,000	New	+$1.53M	﹤0.01%	672
2017 Q2	–	Sell	-450,000	Closed	-$13.4M	–	701
2017 Q1	$13.4M	Hold	450,000	–	–	0.03%	486
2016 Q4	$12.2M	Buy	+450,000	New	+$12.2M	0.03%	493